Tag: terms

NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company’s Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

WARREN, N.J., July 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced today that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197) titled, "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models."

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) will hold a conference call and live audio webcast at 1:00 p.m. (ET) on Thursday, July 31, 2025, to discuss financial results for the quarter ended June 30, 2025. The financial results will be released on Wednesday, July 30, 2025, after the markets close. Interested parties are invited to participate in the call with management which will be followed by a question and answer period with analysts.

EURneffy (neffy^® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

18 July 2025 - Reference is made to the stock exchange announcement published by Prosafe SE ("Prosafe" or the "Company") on 24 April 2025 where it was announced that Prosafe had agreed the terms of a recapitalization (the "Recapitalization") which, inter alia, includes a recapitalization of USD 193 million into 321,635,718 new shares in the Company (the "New Shares") and an offering of up to 17,868,651 warrants to shareholders in the Company as of 16 May 2025 as registered in the Euronext Securities Oslo (VPS) on the record date 20 May 2025 (the "Warrants"), subject to final approval being obtained by all lenders.